Eli Lilly is taking one step out of China so it can gain a firmer foothold with the other. Citing an intention to focus on newer therapies, the U.S. pharma is selling Chinese rights to two legacy antibiotics and a
read moreBiopharma executive pay and drug pricing gin up plenty of headlines on their own. For the second year in a row, a group of investors is trying to spotlight the links between them. More: Investors to AbbVie, J&J, Merck and
read moreEli Lilly’s Taltz has followed Novartis rival Cosentyx into all the diseases it treats. But this time, Lilly wants to be first—and some new phase 3 data could help make that happen. Taltz nailed its endpoints in a spondyloarthritis trial,
read moreThe new treatment involves stimulating cells in the retina with light in a process called ‘photobiomodulation.’ More: First patient recruited in global AMD trial Source: News
read moreThe procedure involves inserting a device directly into the brain to stimulate hearing pathways. More: NHS set to fund brain surgery for deaf children Source: News
read moreTaltz is also approved to treat adults with moderate-to-severe plaque psoriasis. More: Positive results for Eli Lilly’s Taltz in late stage non-radiographic axial spondyloarthritis trial Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals